The EGFR signaling plays a role in signaling the downstream BRAF. Therefore, we conduct testing on KRAS and EGFR mutation in thyroid cancer patients who did not harbor BRAF mutation. The gene discussed is EGFR; the disease is thyroid gland carcinoma.